The Nacubactam Trials Just Proved Something the FDA Needs to Hear About AMR Drug Development

Picture a clinician in an ICU managing a patient with a complicated urinary tract infection that has stopped responding to carbapenems. The culture comes back: carbapenem-resistant Enterobacteriaceae. The options narrow to a handful of last-resort agents, most carrying nephrotoxicity profiles that compound an already critical situation. Now picture a Phase 3 trial that just demonstrated an 89% composite cure rate against exactly that pathogen class — and the regulatory community still has not fully absorbed what the design of that trial means for every AMR sponsor trying to get to market.

The Integral-1 trial, published in The Lancet, evaluated cefepime–nacubactam and aztreonam–nacubactam against imipenem–cilastatin in adults with complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis. The study was global, double-blind, and randomized — the full Phase 3 architecture. Both novel combinations met their primary composite efficacy endpoints against the active comparator. That result matters clinically. But the design choices embedded in how Integral-1 was built carry lessons that extend far beyond this single drug program.

The AMR development space has been hemorrhaging sponsors for a decade, and the reasons are well-documented: unfavorable reimbursement economics, trial recruitment difficulty in a patient population defined by culture-confirmed resistant infections, and persistent regulatory ambiguity around non-inferiority margins in infectious disease. Integral-1 navigated all three. Understanding how it did that — and where the FDA still needs to act — is the more important story.

A Trial Design That Did Not Flinch

The structural challenge in any cUTI/pyelonephritis trial targeting resistant pathogens is patient identification. You cannot randomize patients before culture confirmation without polluting your primary efficacy analysis with susceptible-organism infections that any comparator would clear. Integral-1 enrolled patients with cUTI and acute uncomplicated pyelonephritis across a global, multicentre population — and then executed a double-blind design against imipenem–cilastatin as the active comparator. That is a high bar. Imipenem–cilastatin does not lose often in this indication against susceptible gram-negative organisms. Choosing it as comparator rather than placebo signals methodological confidence, and the FDA and EMA both read that confidence in the submission package.

The imipenem comparator choice also carries a precedent worth examining. The RESTORE-IMI 1 trial, published in Clinical Infectious Diseases in 2020, evaluated imipenem/relebactam against imipenem/colistin in carbapenem-resistant infections — a design forced by the ethics of withholding carbapenem-sparing agents from resistant-pathogen patients. Integral-1 was able to use the parent carbapenem as comparator because the nacubactam combinations were being tested primarily against the susceptible population, with the resistant-pathogen subgroup providing the critical efficacy signal that justifies the AMR label claim. That layered design — broad indication with a resistant-pathogen signal embedded — reflects how the FDA’s Antibacterial Drug Development guidance has evolved. It also reflects a commercial reality: you cannot build a sustainable development program on a resistant-only indication with its razor-thin enrollable population.

Here is the counterintuitive point that most AMR commentary misses. Conventional wisdom says that to earn an AMR drug’s credibility, you must run your pivotal trial exclusively in resistant-pathogen patients. Show the drug working where nothing else does. That logic, taken to its extreme, produces trials that take five years to enroll 200 patients and then fail to reach regulatory significance because the subgroup is statistically underpowered. Integral-1’s design — enrolling the broader cUTI population while preserving a pre-specified resistant-pathogen efficacy analysis — is actually the more rigorous approach to establishing both clinical utility and regulatory approvability. The drug earns the broad label, and the resistant-organism data becomes the prescribing signal that shapes real-world use.

What the Resistance Numbers Demand

The epidemiological backdrop makes getting this design right an urgent priority. According to the CDC’s 2025 report, carbapenem resistance among select Enterobacterales in the United States reached 3.3% in 2024, based on 772 resistant isolates out of 23,673 tested — but the trajectory embedded in that figure is what demands attention. New Delhi metallo-β-lactamase-producing CRE infections surged more than 460% between 2019 and 2023. That is not a resistance trend. That is a resistance emergency moving in slow motion, and the drug development pipeline that should be responding to it is structurally underbuilt.

Nacubactam’s mechanism targets exactly this vulnerability. As a diazabicyclooctane β-lactamase inhibitor, it extends the activity of cefepime and aztreonam into strains producing serine-carbapenemases — the enzyme class driving much of the CRE surge the CDC is tracking. The Integral-1 results confirm that the mechanism translates to clinical outcomes at Phase 3 scale. But confirmatory efficacy data, however strong, does not solve the structural problem upstream of approval: the FDA has not established a sufficiently clear regulatory pathway for sponsors developing novel β-lactam/β-lactamase inhibitor combinations against resistant-pathogen subgroups. The approval of ceftazidime–avibactam in 2015 and meropenem–vaborbactam in 2017 created precedents, but not a reproducible framework. Every subsequent sponsor is navigating by feel.

The FDA’s posture here is understandable — the science is genuinely complex, and non-inferiority margin justification in cUTI depends on assumptions about spontaneous resolution rates that shift with pathogen severity. But incomplete guidance in a therapeutic area facing a 460% resistance surge carries costs that accrue in ICUs, not in Silver Spring conference rooms.

The Approval Pathway AMR Sponsors Are Still Waiting For

Consider what a sponsor team is facing when they open their pre-NDA Type B meeting request for a novel β-lactam/β-lactamase inhibitor combination. They have Phase 3 data structured like Integral-1 — a broad cUTI indication with a resistant-pathogen subgroup. The FDA’s 2022 guidance on developing antibacterial drugs for serious and life-threatening infections asks the sponsor to justify their non-inferiority margin with historical placebo data that, for resistant organisms, either does not exist or was collected in an era when resistance profiles were incomparable to today. That gap is not hypothetical. It is the document sponsors are staring at when they are trying to finalize their statistical analysis plan.

Integral-1’s primary endpoint — a composite of clinical cure and microbiological eradication at a specified test-of-cure visit — is the architecture that resolves part of this problem. By combining the clinical and microbiological endpoints rather than treating them as co-primaries requiring independent success, the design avoids the scenario where a drug clears the bacterium but the patient still has fever, or vice versa, and the trial result becomes uninterpretable. The FDA has accepted this composite structure in prior AMR approvals. What it has not done is codify it as the expected design for resistant-pathogen subgroup analyses — leaving each new sponsor to re-argue the endpoint architecture from scratch in their IND and Type B meetings.

The economic dimension compounds the design problem. The Integral-1 data represents years of development investment by a sponsor willing to run a global, double-blind Phase 3 in an indication where the enrollable population is defined by a microbiological diagnosis that takes 48 to 72 hours to confirm. That timeline creates protocol deviation exposure, per-patient cost structures that exceed most oncology trials, and retention challenges when patients improve clinically before culture results return. The sponsors who can absorb those operational costs are increasingly rare — and the ones who cannot are the generic pharmaceutical companies and smaller biotechs that actually need a clear regulatory signal to justify entering the AMR space at all.

The nacubactam combinations have now cleared the highest evidentiary bar in drug development. Phase 3, double-blind, active-controlled, global, against a comparator that does not lose easily. The clinical community will rightly focus on what these results mean for patients with resistant gram-negative infections. But the regulatory community should focus on what Integral-1’s design means for the next sponsor sitting in front of a blank IND template, trying to decide whether the AMR development pathway is navigable — or whether the 460% surge in NDM-CRE infections will simply outrun the pipeline that is supposed to answer it.

References

1. The Lancet — “Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial”
2. PubMed — Integral-1 trial enrollment numbers, patient population characteristics, and primary endpoint results
3. CDC — “2025 CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria,” including 460% surge in NDM-CRE and 3.3% carbapenem resistance prevalence in the United States
4. PubMed — RESTORE-IMI 1 trial, imipenem/relebactam vs. imipenem/colistin in carbapenem-resistant infections, Clinical Infectious Diseases, 2020